Market Overview

Global Markets for the Treatment & Diagnosis of Sexually Transmitted Diseases (STDs): 2017-2018 to 2023 -


The "Global
Markets for Treatment and Diagnosis of Sexually Transmitted Diseases"

report has been added to's

The scope of this the report includes an overview of the global market
scenario for diagnosis and treatments of sexually transmitted disease
with base year data of 2017, estimations for 2018 and forecast for
2019-2023 using projections of CAGR.

Market data in value terms is provided at global, regional and country
levels for disease areas and treatment by drug class. Market data for
sexually transmitted disease diagnostics is provided for regional
levels, with details on test types.

The report focuses on key sectional assessments for major disease areas
such as chlamydia, genital herpes, HIV and hepatitis, among others, and
provides detailed analysis of epidemiology, historic and current disease
incidence trends, therapeutic interventions and diagnostic overview.

It forecasts the global market by drug class for treatment of STDs and
discusses market data for antibiotics, antivirals/antiretrovirals and
other treatments.

Diagnostic test types such as enzyme immunoassays (EIA) and ELISA, PCR,
rapid diagnostics and others, are detailed with market data current and

Market Trends

  • Increasing Incidence of STDs
  • STD Awareness and Screening Services
  • Development of Test Kits with High Sensitivity for Low Resource

Market Challenges

  • Underestimating the Risk of Contracting the Disease
  • Social Stigma Associated with STDs
  • Rising Incidence of Antibiotic Resistance
  • Lack of Prenatal Screening for STDs

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Global Market Overview and Trends

Chapter 4 Disease Overview

Chapter 5 STD Diagnosis and Treatment Options

Chapter 6 The North American Market Breakdown

Chapter 7 The European Market Breakdown

Chapter 8 The Asia-Pacific Market Breakdown

Chapter 9 Rest of World Market Breakdown

Chapter 10 Regulatory Structure

Chapter 11 Pipeline Analysis

Chapter 12 Competitive Landscape and Key Developments

Chapter 13 Company Profiles

  • Abbott Laboratories
  • Abbvie Inc.
  • Agilent Technologies Inc.
  • Becton, Dickinson & Company
  • Bio-Rad Laboratories, Inc
  • Biomerieux Inc.
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Bristol-Myers Squibb Company
  • Cepheid Inc.
  • Gilead Sciences Inc.
  • Glaxosmithkline PLC
  • Hoffmann-La Roche Inc.
  • Hologic Inc.
  • Janssen Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Meridian Life Science Inc.
  • Novartis AG
  • Pfizer Inc.
  • Promega Corp.
  • Qiagen N.V.
  • Quidel Corp
  • Thermo Fisher Scientific Inc.

For more information about this report visit

View Comments and Join the Discussion!